**Supplementary Table 2.** Factors associated with reaching the glycemic target (HbA1c ≤7%) within 24 weeks according to the treatment regimen

<table>
<thead>
<tr>
<th>Variable</th>
<th>Quadruple therapy</th>
<th>GLP-1RA therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Adjusted OR&lt;sup&gt;a&lt;/sup&gt; (95% CI)</td>
<td>P value</td>
</tr>
<tr>
<td>Age, yr</td>
<td>1.00 (0.98–1.01)</td>
<td>0.67</td>
</tr>
<tr>
<td>Male sex</td>
<td>0.97 (0.74–1.28)</td>
<td>0.88</td>
</tr>
<tr>
<td>BMI, kg/m&lt;sup&gt;2&lt;/sup&gt;</td>
<td>1.00 (0.97–1.04)</td>
<td>0.80</td>
</tr>
<tr>
<td>HbA1c at baseline, %</td>
<td>0.97 (0.85–1.11)</td>
<td>0.60</td>
</tr>
<tr>
<td>Diabetes duration, yr</td>
<td>0.99 (0.97–1.02)</td>
<td>0.61</td>
</tr>
<tr>
<td>C-peptide at baseline, ng/mL</td>
<td>0.96 (0.80–1.15)</td>
<td>0.64</td>
</tr>
</tbody>
</table>

HbA1c, glycosylated hemoglobin; OR, odds ratio; CI, confidence intervals; BMI, body mass index.

<sup>a</sup> Multivariate logistic regression analysis with adjusting for age, sex, body mass index, disease duration, baseline HbA1c, treatment regimen (quadruple therapy vs. glucagon-like peptide-1 receptor agonist therapy), and baseline C-peptide levels.